Developer docs
API playgroundTry for free, no card

Search company profiles

Granules India

Full company profile

uuid0009yno

Namestring
Granules India
Legal namestring
Granules India Limited
Company typeenum
Public
Founded yearint
1991
Short descriptiontext

Granules India is a vertically integrated pharmaceutical manufacturer producing APIs, formulation intermediates, and finished dosages across 10 facilities in India, the US, and Switzerland, serving 300+ pharmaceutical customers in 80+ countries with 69 ANDA approvals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceutical manufacturing, active pharmaceutical ingredients, finished dosage formulations, pharmaceutical formulation intermediates, peptide CDMO services
Industry2 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
Product category
Generic Pharmaceuticals Manufacturing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Active Pharmaceutical Ingredients (API)
TypeOne Time License
Description

High-volume API manufacturing including paracetamol, metformin, and other essential pharmaceuticals. One of the world's largest paracetamol makers.

constructionworld.in
2Pharmaceutical Formulation Intermediates (PFI)
TypeOne Time License
Description

Compresso product line including directly compressible granules for various molecules used in tablet manufacturing by customers

constructionworld.in
3Finished Dosages (FDF)
TypeOne Time License
Description

Finished pharmaceutical products including tablets, capsules, and other dosage forms sold to pharmaceutical companies and distributors globally

constructionworld.in
4CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services through acquired Senn Chemicals for peptide therapeutics and other complex molecules

moneycontrol.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Peptides CDMO Platform
Description

Contract development and manufacturing organization (CDMO) platform for peptide-based therapeutics, enhanced by the acquisition of Swiss firm Senn Chemicals AG

constructionworld.in
+1 more record
Core offering1 text field

Granules India is a vertically integrated pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD) for global pharmaceutical companies. It is one of the world's largest paracetamol manufacturers and is expanding into complex generics and peptide-based contract development and manufacturing organization (CDMO) services following its acquisition of Swiss firm Senn Chemicals AG.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue growth of 20% YoY to Rs 53,656 million in FY26
+3 more records
Product overview1 text field

Granules India is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with over 40 years of proven performance. The company operates across three main product categories: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulations Intermediates (PFI), and Finished Dosages (FD). The company is one of the world's largest paracetamol manufacturers. Recent strategic initiatives include expansion into complex generics and peptide-based contract development and manufacturing (CDMO) services, following the acquisition of Swiss CDMO firm Senn Chemicals AG. Granules serves over 300 customers in more than 80 countries across 10 manufacturing facilities in India, the United States, and Switzerland.

Product and service6 records
1Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

High-quality active pharmaceutical ingredients manufactured at ICH quality standards, serving as the foundation for finished dosage formulations. Products include APIs across therapeutic categories including analgesics, antihemorrhagics, antiretroviral, antihistamine, antidepressant, antifungal, anticonvulsant, expectorant, muscle relaxant, anti-ulcerative, anticancer, antihypertensive, antibiotic, hypoglycemic, anti-inflammatory agents, and immunomodulatory agents. Sold to global generic pharmaceutical manufacturers.

2Pharmaceutical Formulation Intermediates (PFI)
CategoryPharmaceutical Formulation Intermediates
Description

Pre-formulated directly compressible granules serving as intermediate products for tablet manufacturing by pharmaceutical customers. Includes the Compresso product line containing Paracetamol (PAP series in various concentrations like 90%, 96%, 87%), Metformin (MF series), Methocarbamol, Ibuprofen (IBU series), Guaifenesin (GGF series), and other therapeutic compounds.

3Finished Dosages (FD)
CategoryFinished Dosages
Description

Ready-to-market finished dosage forms including tablets, capsules, oral solutions, injectables, and extended-release formulations. Products span multiple therapeutic areas such as pain management, diabetes, cardiovascular health, HIV/AIDS, oncology, and neurological disorders. Sold to pharmaceutical companies and distributors globally.

4Acetaminophen/Paracetamol API and Formulations
CategoryKey API Product
Description

Nonnarcotic analgesic and antipyretic drug. Granules India is one of the world's largest paracetamol manufacturers. Available in multiple forms including suppository, extended-release tablet, and intravenous solution. Available as both API and finished dosage formulations.

5Metformin Hydrochloride API and Formulations
CategoryKey API Product
Description

Anti-diabetic biguanide medication that lowers glucose production in the liver and increases body sensitivity to insulin. Available as tablet, extended-release tablet, solution, and extended-release suspension. Sold as both API and finished dosage formulations.

6Peptide CDMO Services (via Senn Chemicals AG)
CategoryCDMO Services
Description

Contract development and manufacturing organization (CDMO) services for peptide-based therapeutics, leveraging Senn Chemicals AG's peptide synthesis expertise combined with Granules India's manufacturing scale. Targeted at pharmaceutical companies developing GLP-1, oncology, and other complex peptide therapeutics.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Senn Chemicals AG
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Granules India acquired Swiss CDMO firm Senn Chemicals AG for CHF 20 million (approximately INR 192.5 crore) in February 2025 to expand into peptide therapeutics and CDMO services. The acquisition leverages Senn's peptide synthesis expertise with Granules' manufacturing capabilities to deliver peptide-based solutions globally.

openpr.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian pharmaceutical company with API manufacturing, generic formulations, and biosimilars businesses, with major US presence. Comparable to Granules India in API+finished dosage model, regulated market focus, and complex generics expansion.

TypeDirect peer
Description

Indian API manufacturer specializing in complex APIs and custom synthesis for global pharma. Comparable to Granules India on API manufacturing focus, US regulatory dependence, and high-volume production capabilities.

3Sun Pharmaceutical Industries
TypeBroad incumbent
Description

Largest Indian pharmaceutical company with extensive API, generic, and specialty drug portfolio. Comparable to Granules India on US generics exposure and API manufacturing, but operates at significantly larger scale and broader therapeutic scope.

TypeDirect peer
Description

Indian API and formulation manufacturer with strong presence in generic ARV APIs and synthesis capabilities. Highly comparable to Granules India on API manufacturing scale, US generics exposure, and contract development services.

TypeDirect peer
Description

Indian pharmaceutical company producing APIs and finished formulations with US market presence. Comparable to Granules India on API manufacturing scale, US generics focus, and manufacturing network in India.

TypeDirect peer
Description

Indian pharmaceutical company with API and finished dosage manufacturing with focus on complex generics including oncology. Comparable to Granules India on complex generics strategy, US ANDAs, and oncology pipeline development.

TypeBroad incumbent
Description

Indian pharmaceutical company with API manufacturing, formulations, biosimilars, and consumer health businesses. Comparable to Granules India on API manufacturing and US generics focus, with broader product portfolio and biosimilars presence.

TypeDirect peer
Description

Indian pharmaceutical company manufacturing APIs and finished generic formulations with strong US presence. Comparable to Granules India in generic dosage forms, US market dependence, and investment in complex generics.

TypeDirect peer
Description

Indian vertically integrated generic pharmaceutical manufacturer producing APIs, formulations, and finished dosages with significant US market exposure. Directly comparable to Granules India in API-to-finished dosage business model and US generics focus.

TypeDirect peer
Description

Indian generic pharmaceutical manufacturer with API and finished dosage capabilities serving regulated and emerging markets. Comparable to Granules in vertical integration, US FDA exposure, and complex generics pipeline expansion.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Granules India

Generic Pharmaceuticals Manufacturinggranulesindia.com

Granules India is a vertically integrated pharmaceutical manufacturer producing APIs, formulation intermediates, and finished dosages across 10 facilities in India, the US, and Switzerland, serving 300+ pharmaceutical customers in 80+ countries with 69 ANDA approvals.

Granules India firmographics

Firmographics
Name
Granules India
Legal name
Granules India Limited
Website
https://granulesindia.com
Company type
Public
Founded year
1991
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Granules India is a vertically integrated pharmaceutical manufacturer producing APIs, formulation intermediates, and finished dosages across 10 facilities in India, the US, and Switzerland, serving 300+ pharmaceutical customers in 80+ countries with 69 ANDA approvals.
Ownership category
akta.pro rank

Granules India industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Generic pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • Finished dosage formulations
  • Pharmaceutical formulation intermediates
  • Peptide CDMO services

Where Granules India is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices8 records

Markets served

Granules India business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Active Pharmaceutical Ingredients (API): High-volume API manufacturing including paracetamol, metformin, and other essential pharmaceuticals. One of the world's largest paracetamol makers.
  2. Pharmaceutical Formulation Intermediates (PFI): Compresso product line including directly compressible granules for various molecules used in tablet manufacturing by customers
  3. Finished Dosages (FDF): Finished pharmaceutical products including tablets, capsules, and other dosage forms sold to pharmaceutical companies and distributors globally
  4. CDMO Services: Contract development and manufacturing services through acquired Senn Chemicals for peptide therapeutics and other complex molecules

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Granules India product offering

Product offering

Core offering

Granules India is a vertically integrated pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD) for global pharmaceutical companies. It is one of the world's largest paracetamol manufacturers and is expanding into complex generics and peptide-based contract development and manufacturing organization (CDMO) services following its acquisition of Swiss firm Senn Chemicals AG.

Product overview

Granules India is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with over 40 years of proven performance. The company operates across three main product categories: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulations Intermediates (PFI), and Finished Dosages (FD). The company is one of the world's largest paracetamol manufacturers. Recent strategic initiatives include expansion into complex generics and peptide-based contract development and manufacturing (CDMO) services, following the acquisition of Swiss CDMO firm Senn Chemicals AG. Granules serves over 300 customers in more than 80 countries across 10 manufacturing facilities in India, the United States, and Switzerland.

Differentiator

Problem solved

Functional benefit

Brands

  • Peptides CDMO Platform: Contract development and manufacturing organization (CDMO) platform for peptide-based therapeutics, enhanced by the acquisition of Swiss firm Senn Chemicals AG
  • Complex Generics

Products and services

  • Active Pharmaceutical Ingredients (APIs) High-quality active pharmaceutical ingredients manufactured at ICH quality standards, serving as the foundation for finished dosage formulations. Products include APIs across therapeutic categories including analgesics, antihemorrhagics, antiretroviral, antihistamine, antidepressant, antifungal, anticonvulsant, expectorant, muscle relaxant, anti-ulcerative, anticancer, antihypertensive, antibiotic, hypoglycemic, anti-inflammatory agents, and immunomodulatory agents. Sold to global generic pharmaceutical manufacturers.
  • Pharmaceutical Formulation Intermediates (PFI) Pre-formulated directly compressible granules serving as intermediate products for tablet manufacturing by pharmaceutical customers. Includes the Compresso product line containing Paracetamol (PAP series in various concentrations like 90%, 96%, 87%), Metformin (MF series), Methocarbamol, Ibuprofen (IBU series), Guaifenesin (GGF series), and other therapeutic compounds.
  • Finished Dosages (FD) Ready-to-market finished dosage forms including tablets, capsules, oral solutions, injectables, and extended-release formulations. Products span multiple therapeutic areas such as pain management, diabetes, cardiovascular health, HIV/AIDS, oncology, and neurological disorders. Sold to pharmaceutical companies and distributors globally.
  • Acetaminophen/Paracetamol API and Formulations Nonnarcotic analgesic and antipyretic drug. Granules India is one of the world's largest paracetamol manufacturers. Available in multiple forms including suppository, extended-release tablet, and intravenous solution. Available as both API and finished dosage formulations.
  • Metformin Hydrochloride API and Formulations Anti-diabetic biguanide medication that lowers glucose production in the liver and increases body sensitivity to insulin. Available as tablet, extended-release tablet, solution, and extended-release suspension. Sold as both API and finished dosage formulations.
  • Peptide CDMO Services (via Senn Chemicals AG) Contract development and manufacturing organization (CDMO) services for peptide-based therapeutics, leveraging Senn Chemicals AG's peptide synthesis expertise combined with Granules India's manufacturing scale. Targeted at pharmaceutical companies developing GLP-1, oncology, and other complex peptide therapeutics.

Quantifiable outcome

  • Revenue growth of 20% YoY to Rs 53,656 million in FY26
  • +3 more outcomes

Companies that use Granules India

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Granules India technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Granules India partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Senn Chemicals AGcoreStrategic or Co-development Partner · 1 February 2025Granules India acquired Swiss CDMO firm Senn Chemicals AG for CHF 20 million (approximately INR 192.5 crore) in February 2025 to expand into peptide therapeutics and CDMO services. The acquisition leverages Senn's peptide synthesis expertise with Granules' manufacturing capabilities to deliver peptide-based solutions globally.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Granules India competitors and assessment

Company assessment

Direct peers

  • Dr. Reddy's Laboratories: Indian pharmaceutical company with API manufacturing, generic formulations, and biosimilars businesses, with major US presence. Comparable to Granules India in API+finished dosage model, regulated market focus, and complex generics expansion.
  • Divi's Laboratories: Indian API manufacturer specializing in complex APIs and custom synthesis for global pharma. Comparable to Granules India on API manufacturing focus, US regulatory dependence, and high-volume production capabilities.
  • Laurus Labs: Indian API and formulation manufacturer with strong presence in generic ARV APIs and synthesis capabilities. Highly comparable to Granules India on API manufacturing scale, US generics exposure, and contract development services.
  • Ipca Laboratories: Indian pharmaceutical company producing APIs and finished formulations with US market presence. Comparable to Granules India on API manufacturing scale, US generics focus, and manufacturing network in India.
  • Natco Pharma: Indian pharmaceutical company with API and finished dosage manufacturing with focus on complex generics including oncology. Comparable to Granules India on complex generics strategy, US ANDAs, and oncology pipeline development.
  • Lupin Limited: Indian pharmaceutical company manufacturing APIs and finished generic formulations with strong US presence. Comparable to Granules India in generic dosage forms, US market dependence, and investment in complex generics.
  • Aurobindo Pharma: Indian vertically integrated generic pharmaceutical manufacturer producing APIs, formulations, and finished dosages with significant US market exposure. Directly comparable to Granules India in API-to-finished dosage business model and US generics focus.
  • Cipla: Indian generic pharmaceutical manufacturer with API and finished dosage capabilities serving regulated and emerging markets. Comparable to Granules in vertical integration, US FDA exposure, and complex generics pipeline expansion.

Broad incumbents

  • Sun Pharmaceutical Industries: Largest Indian pharmaceutical company with extensive API, generic, and specialty drug portfolio. Comparable to Granules India on US generics exposure and API manufacturing, but operates at significantly larger scale and broader therapeutic scope.
  • Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical company with API manufacturing, formulations, biosimilars, and consumer health businesses. Comparable to Granules India on API manufacturing and US generics focus, with broader product portfolio and biosimilars presence.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Granules India social profiles

Digital presence

Granules India compliance and trust

Trust signal

Compliance7 records

Granules India financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Granules India leadership team

Management profile

Number of profiles

Profiles4 records

Granules India subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Granules India funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Granules India M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Granules India

What does Granules India do?

Granules India is a vertically integrated pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD) for global pharmaceutical companies. It is one of the world's largest paracetamol manufacturers and is expanding into complex generics and peptide-based contract development and manufacturing organization (CDMO) services following its acquisition of Swiss firm Senn Chemicals AG.

Is Granules India a public or private company?

Granules India is a public company. It is classified as public and is currently operating.

When was Granules India founded?

Granules India was founded in 1991. It employs 1,001 to 5,000 people.

Where is Granules India based?

Granules India is headquartered in Hyderabad, India, in the Asia region.

How does Granules India make money?

Four revenue lines are on record. Active Pharmaceutical Ingredients (API) is the primary driver. The others are pharmaceutical Formulation Intermediates (PFI), finished Dosages (FDF) and CDMO Services.

Who are Granules India's main competitors?

Direct peers on record are Dr. Reddy's Laboratories, Divi's Laboratories, Laurus Labs, Ipca Laboratories, Natco Pharma, Lupin Limited, Aurobindo Pharma and Cipla. Broad incumbents are Sun Pharmaceutical Industries and Zydus Lifesciences (Cadila Healthcare).

Does Granules India have an API?

No public API is recorded for Granules India.

What industry is Granules India in?

Granules India's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CNBCTV18Zydus Lifesciences, Granules India offer growth opportunities over next 3-5 years: Shanika Capital - CNBC TV18Shanika Capital's Anmol Ganjoo sees growth opportunities in Zydus Lifesciences and Granules India over the next 3-5 years, citing earnings growth and capital allocation. He notes Granules India operates at 75% capacity despite an FDA warning letter, and expects CDMO opportunities from global supply chain shifts.Simply Wall StWhat Granules India Bulls Got RightGranules India reported Q2 2027 revenue of ₹15,706.59m and net income of ₹1,818.37m, up from Q2 2026, with net margin rising to 11.6%. The stock trades at ₹800, above the selected Narrative's fair value, implying the price assumes cost pressures remain contained.CNBCTV18Granules India expects North America growth to continue, plans five product launches - CNBC TV18Granules India expects North America to continue growing, with five product launches planned over the next two quarters. The company reported Q2 revenue of ₹1,559 crore and net profit of ₹181 crore, with the US site driving growth. It also sees potential in controlled substances and complex generics.Business News TodayBuy Granules India; target of Rs 950: Emkay Global Financial- Moneycontrol.comEmkay Global Financial cut its earnings estimates on Granules India by about 4% and retained a BUY rating with a target price of Rs950. The cut reflects lower EBITDA margin and higher input costs, while the company maintains its full-year guidance for Senn.CNBCTV18Here are five pharma and healthcare stocks that will be reacting to their Q2 results today - CNBC TV18Five pharma and healthcare stocks—Granules India, Wockhardt, SPARC, Krsnaa Diagnostics, and Akums Drugs—reported their September quarter results on November 3. Granules India saw revenue growth but margin softening, while Akums Drugs reported net profit more than doubling to ₹112.8 crore. The results were reported after market hours on Monday.TradingViewNews by CNBC TV18 on TradingView, 2026-11-03Five pharma and healthcare stocks reported Q2 results on November 3, with Granules India, Wockhardt, SPARC, Krsnaa Diagnostics, and Akums Drugs all posting revenue and profit figures. Akums Drugs saw net profit more than double to ₹112.8 crore, while SPARC's losses narrowed to ₹24.96 crore. The results were reported after market hours on Monday.TradingViewGranules India shares in focus on posting 39% jump in Q2 profitGranules India shares are in focus on November 3 after the company reported a 39.2% year-on-year net profit jump to Rs 182 crore in Q2FY17. Revenue rose 20.3% to Rs 1,560 crore, and EBITDA margin improved to 21.6%. The stock closed down 2.38% in the previous session.Business News TodayGranules India shares in focus on posting 39% jump in Q2 profit- Moneycontrol.comGranules India shares will be watched on November 3 after the company reported a 39.2% year-on-year net profit jump to Rs 182 crore in Q2FY17. Revenue rose 20.3% to Rs 1,560 crore, and EBITDA margin improved to 21.6%. The stock closed at Rs 819.55, down 2.38%.Nate그라뉼스 인디아, 2분기 순이익 40% 급증…북미 매출 호조 : 네이트 뉴스Granules India's Q2 net profit rose 39% to 18.2 billion rupees, driven by new product launches and North American sales, which accounted for 72% of revenue. Operating costs increased 18.5%, with raw material costs up 23.2%. The company expects cost pressures to persist and plans to pass some costs to customers.BusinessLineGranules India’s Q2 net up 39% at ₹182 croreGranules India reported a 39% net profit increase to ₹182 crore in Q2 FY27, with revenue up 20% to ₹1,560 crore. The company cited higher input and logistics costs from West Asia tensions, and noted a US FDA audit at its Gagillapur site.